Women with heart failure with preserved ejection fraction (HFpEF) and obesity, with or without diabetes, show benefits from the GLP-1 receptor agonist semaglutide just like men do. The study analyzed trials comparing semaglutide with a placebo on over 1,000 participants, with similar benefits for both sexes. Women lost more weight but had similar improvements in heart failure symptoms compared to men. The study highlights sex-related differences in HFpEF pathophysiology and treatment response, including the reduction in NT-proBNP levels. Semaglutide also improved NYHA functional class and was more effective than SGLT2 inhibitors, especially in symptomatic patients. The results have important implications for clinical care and research.
Source link
Semaglutide Equally Effective in Women With HFpEF, Obesity
